Tive L, et al. - Researchers conducted a pooled analysis of data from phase III placebo-controlled clinical trials of patients with moderate-to-severe osteoarthritis (OA) of the knee or hip to assess the efficacy (four trials) and safety (nine trials) of tanezumab. The analysis included subgroup analyses of at-risk patients with diabetes, severe OA symptoms, and those aged ≥65 years. The patients were provided intravenous tanezumab, tanezumab plus an oral NSAID (naproxen, celecoxib, or diclofenac), active comparator (naproxen, celecoxib, diclofenac, or oxycodone), or placebo. Findings indicated that OA patients including patients with diabetes, severe OA symptoms, or aged ≥65 years, consistently achieved significant improvement of pain, physical function, and PGA with Tanezumab. At-risk patient subgroups did not display increased safety risk.